Miguel Patricio and Albert Bourla are prominent business executives who both became CEOs of major companies in 2019, but there is no public confirmation that they are relatives, business partners or longtime colleagues. Their clearest documented connection is that both appeared in Feigen Advisors’ S&P 250 New CEO Class of 2019: Bourla at Pfizer and Patricio at Kraft Heinz.
Their routes to those jobs were very different. Patricio arrived at Kraft Heinz after a career spanning consumer goods, beverages and global marketing. Bourla reached Pfizer’s top job after more than 25 years inside the pharmaceutical company, beginning in animal health.
As of October 1, 2026, their careers have diverged again. Patricio is an AB InBev director and is no longer on the Kraft Heinz board, while Bourla remains Pfizer’s Chairman and CEO.
What connects Miguel Patricio and Albert Bourla?
The most concrete link is timing. Albert Bourla became Pfizer CEO on January 1, 2019. Miguel Patricio became Kraft Heinz CEO on June 25 of the same year.
That shared milestone put them in the same cohort of newly appointed chief executives studied by Feigen Advisors. It does not establish a deeper relationship between the two men.
Their documented career histories also developed in separate corporate networks. Patricio worked across consumer businesses before spending years at Ambev and AB InBev, then moving to Kraft Heinz. Bourla joined Pfizer in 1993 and built most of his career within that company.
There is therefore no basis for presenting the pair as co-founders, relatives or established business partners. Nor would it be accurate to claim they have never met; the available public record simply does not establish a significant direct relationship.
Miguel Patricio’s career before Kraft Heinz
Miguel Patricio is a Portuguese business executive with a background in consumer products and marketing. He studied Business Administration at Fundação Getulio Vargas in São Paulo.
Before joining Ambev, he held positions at companies including Johnson & Johnson, Coca-Cola and Philip Morris. He joined Ambev in 1998 and developed a career that increasingly combined brand management with regional leadership.
Contemporaneous AB InBev records place him in North American leadership from the mid-2000s, followed by responsibility for Asia Pacific from 2008. In 2012, he became the brewer’s global chief marketing officer.
That background made Patricio an unusual but understandable choice for Kraft Heinz. He arrived from the beverage sector rather than from another packaged-food company, bringing experience built around large consumer brands, international markets and marketing strategy.
His move to Kraft Heinz
Kraft Heinz initially announced that Patricio would become CEO on July 1, 2019. That date is still repeated on some biography pages, but it is not the final effective date.
A later Kraft Heinz SEC filing states that his start was brought forward to June 25, 2019. That is the date that should be used for his official appointment.
Patricio took over at a difficult point for Kraft Heinz, when the company was rethinking how it managed and invested in its portfolio of long-established food brands.
In a 2023 Fortune interview, Patricio said his first priority after arriving was “people and culture.” He described spending his early months visiting teams and factories before turning more heavily toward strategy.
That comment is useful because it shows how Patricio described his own priorities. It should not be read as proof that any one management approach caused Kraft Heinz’s later performance.
Patricio became Chair of the Kraft Heinz board in May 2022 while continuing as CEO. His CEO tenure ended in December 2023, with Carlos Abrams-Rivera taking over as chief executive on January 1, 2024.
Patricio stayed involved with the company after leaving the CEO role. He continued in board leadership and later served as Executive Chair during 2025.
Where Miguel Patricio is now
Patricio’s Kraft Heinz status changed again in 2026.
He was still a Kraft Heinz director in February 2026, but the company’s 2026 proxy statement said he was not standing for re-election at the May 14 annual meeting. The resulting board election did not include him.
That matters because some current and recently published biographies still describe Patricio as a Kraft Heinz director. Those descriptions are stale.
His current verified public-company role is back at AB InBev. Shareholders elected him to the brewer’s board on April 29, 2026 for a four-year term ending after the 2030 annual general meeting, according to AB InBev’s shareholder announcement filed with the SEC.
In career terms, that creates a clear loop: Patricio spent years as an operating executive at Ambev and AB InBev, left to lead Kraft Heinz, and later returned to AB InBev in a governance role.
Albert Bourla’s path through Pfizer
Albert Bourla followed a very different route.
He trained as a veterinarian and earned both a Doctor of Veterinary Medicine degree and a PhD in Biotechnology of Reproduction from Aristotle University of Thessaloniki. He joined Pfizer in 1993 in its Animal Health business in Greece.
Over the following decades, Bourla moved through a series of increasingly senior roles spanning animal health, established pharmaceutical products, vaccines, oncology, consumer healthcare and Pfizer’s innovative medicines businesses.
He became Pfizer’s chief operating officer in 2018. Later that year, the company announced that he would succeed Ian Read as CEO.
The appointment became effective on January 1, 2019, according to Pfizer’s CEO succession announcement.
One year later, on January 1, 2020, Bourla also became Chairman of Pfizer’s board while retaining the CEO position.
Bourla and the Pfizer-BioNTech vaccine programme
The COVID-19 pandemic became the most publicly visible period of Bourla’s tenure.
Pfizer worked with German biotechnology company BioNTech on an mRNA vaccine against COVID-19. In a first-person Harvard Business Review article, Bourla described challenging Pfizer’s organisation in March 2020 to “make the impossible possible” and identified BioNTech and its chief executive, Uğur Şahin, as central partners in the effort.
The distinction between executive leadership and scientific development is important. Bourla led Pfizer during the programme, but the vaccine was the work of Pfizer, BioNTech and their scientific, clinical, manufacturing and regulatory teams rather than the achievement of one individual.
The regulatory milestone came on December 11, 2020, when the US Food and Drug Administration issued the vaccine’s initial emergency use authorization. The FDA’s documentation refers to it as the Pfizer-BioNTech COVID-19 vaccine.
Why their career paths are so different
The most useful comparison between Patricio and Bourla is not a personal one. It is the way they reached the CEO office.
Patricio built experience across several consumer-facing businesses. His career combined marketing, brand management and regional leadership before Kraft Heinz recruited him from outside the company.
Bourla developed almost entirely inside Pfizer. His scientific training was followed by decades of operational and commercial leadership across different parts of the pharmaceutical business before he became CEO.
That makes their 2019 appointments examples of two different succession models: an external executive brought in after a long cross-company consumer career, and an internal executive promoted after decades within one science-based organisation.
Neither route, on its own, says which leader was more effective. It does explain why the two executives had very different experience when they reached the top jobs in the same year.
Where Albert Bourla is now
Bourla remains at Pfizer.
As of October 1, 2026, Pfizer’s current leadership page identifies him as Chairman and Chief Executive Officer. His continued tenure contrasts with Patricio’s post-CEO transition into board work.
For readers trying to understand why Miguel Patricio and Albert Bourla appear together online, the answer is therefore fairly specific: both joined the 2019 class of new CEOs at major multinational companies, but their industries, professional histories and present roles are separate.
Patricio is now back at AB InBev as a director after ending his Kraft Heinz board service in 2026. Bourla continues to lead Pfizer as Chairman and CEO.
